Utah Medical Products IncUTMD

Utah Medical Products Inc. is a small-cap medical device maker whose main act is selling blood-pressure monitoring and blood-management kit-Deltran monitors and arterial blood collection systems-into hospitals and clinics. The company’s product pages promise “healthcare solutions” for labour and delivery, neonatal care, women’s health, urology, and surgery, but the filings suggest the real solution it’s selling is liquidity preservation. With $87.4 million in cash and equivalents as of 31 March 2026, it’s sitting on a tidy pile, yet the same 10-Q shows the company spent only $130,000 on new plant and equipment in the quarter. The contrast between the glossy catalogue and the bare-bones capex line tells you everything about where management’s priorities lie.

The company’s revenue clocked in at $8.7 million in the quarter to 31 March 2026, with operating income of $2.6 million and net income per diluted share of $0.82. Net cash provided by operating activities was $3.1 million, which is healthy for a company of this size, but the $8.7 million of inventory-up $830,000 in the quarter-raises the question of whether sales are keeping pace with production. Research and development spending was a modest $154,000, a figure that would struggle to fund even a single clinical trial, let alone a pipeline. The company’s website cheerfully lists its blood-pressure and blood-management products, but there’s no evidence in the filings of any blockbuster launches or regulatory milestones in the period covered.

The 10-Q for the quarter ending 31 March 2026 shows total assets of $124.4 million against liabilities of $4.0 million, leaving shareholders’ equity at $120.4 million. Cash and equivalents were $87.4 million, up from $84.3 million at the start of the year, while inventory rose to $8.7 million. The company’s 8-K on 23 July 2026 disclosed approval of named executive officer compensation on an advisory basis, which is corporate parlance for “the board asked and they all said yes.” The same filing confirms the board’s compensation discussion and analysis was signed off without dissent. Meanwhile, the company’s conflict minerals filing disclosed that Utah Medical does not purchase any conflict minerals directly from mines, smelters, or refiners, relying instead on suppliers to handle the filing trail.

If you’re looking for a chart, the company trades on the OTCQB under the symbol UTMD. Trading volume is thin, with no meaningful price momentum to speak of in the filings, so any chart you see will reflect micro-cap liquidity rather than fundamental momentum. The company’s submissions JSON on the SEC site lists 8-Ks, 10-Qs, and the usual corporate housekeeping, but there’s no evidence of any material news flow that would move the needle beyond the ordinary course. The product rail shows a stable line of blood-pressure and blood-management devices, but no evidence of expansion into adjacent segments or new geographies in the period covered.

The tension in this file is straightforward: Utah Medical is a cash-rich, low-capex, low-R&D medical device outfit with a steady if unspectacular product line. The question investors have to ask is whether the board’s preference for liquidity over investment is a virtue born of prudence or a vice born of inertia. The next catalyst that would change the file would be a material product launch, a regulatory approval, or a step-change in R&D spending that actually moves the dial. Until then, the company remains a quiet keeper of cash rather than a builder of the future. (source: Utah Medical Products Inc., 10-Q for the period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/706698/000109690626000767/utmd-20260331_10q.htm)